The Rilutek® (riluzole) global early access programme: An open-label safety evaluation in the treatment of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 2, Issue 3, 2001, Pages 153-158

  Debove, C ^a   Zeisser, P ^a   Salzman, P M ^a   Powe, L K ^a   Truffinet, P ^a  

^a SANOFI   (France)

Author keywords

Amyotrophic lateral sclerosis; Early access programme; Riluzole (Rilutek ); Safety

Indexed keywords

PLACEBO; RILUZOLE; ALANINE AMINOTRANSFERASE; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; DYSPHAGIA; FEMALE; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RECORDING; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SYMPTOM; ADOLESCENT; BLOOD; IATROGENIC DISEASE; MORTALITY; NEUTROPENIA; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; AMYOTROPHIC LATERAL SCLEROSIS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMAN; MALE; MIDDLE AGE; NEUTROPENIA; RILUZOLE; SURVIVAL ANALYSIS;

EID: 0035543029     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/146608201753275508     Document Type: Article

References (20)

1. The natural history of ALS in a specified population, with comments on risk factors, prognosis and symptomatic treatments
2. Motor neuron disease (amyotrophic lateral sclerosis)
3. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis
4. Excitotoxicity in ALS
5. The role of excitotoxicity in neurological disease
6. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
7. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo
8. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed by Xenopus oocytes
9. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1
10. Antagonism by riluzole of entry of calcium evoked by MNSA and veratridine in rat cultured granule cells: Evidence for a dual mechanism of action
11. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices
12. Neuroprotective effects of riluzole in ALS CSF toxicity
13. The pharmacology and mechanism of action of riluzole
14. Effects of riluzole on glutamatergic neurotransmission in the mammalian central nervous system and other pharmacological effects
15. A controlled trial of riluzole in amyotrophic lateral sclerosis
16. Dose ranging study of riluzole in Amyotrophic Lateral Sclerosis
17. Classification of Neuromuscular Disease
18. Clinical trials of riluzole in patients with ALS
19. The tolerability and adverse event profile of riluzole